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Although there is a wide variety of antidepressants with different mechanisms of action available, the efficacy of
treatment is not satisfactory. Genetic factors are presumed to play a role in differences in medication response;
however, available evidence is controversial. Even genome-wide association studies failed to identify genes or
regions which would consequently influence treatment response. We conducted a literature review in order to
uncover possible mechanisms concealing the direct effects of genetic variants, focusing mainly on reports from
large-scale studies including STAR*D or GENDEP. We observed that inclusion of environmental factors, gene-
environment and gene-gene interactions in the model improves the probability of identifying genetic modulator effects
of antidepressant response. It could be difficult to determine which allele of a polymorphism is the risk factor for poor
treatment outcome because depending on the acting environmental factors different alleles could be advantageous to
improve treatment response. Moreover, genetic variants tend to show better association with certain intermediate
phenotypes linked to depression because these are more objective and detectable than traditional treatment outcomes.
Thus, detailed modeling of environmental factors and their interactions with different genetic pathways could significantly
improve our understanding of antidepressant efficacy. In addition, the complexity of depression itself demands a more
comprehensive analysis of symptom trajectories if we are to extract useful information which could be used in the
personalization of antidepressant treatment.Introduction
Major depressive disorder (MDD) is a great burden for
our society owing to its high prevalence rate and disab-
ling symptoms [1]. Effective medications against MDD
show significantly better efficacy compared to placebo,
especially in severe cases [2]. However, less than half of
the patients achieve remission with the first prescribed
antidepressant [3]. Family studies indicate that variability
of antidepressant response shows a high heritability; there-
fore, just as in the case of the development of MDD, the
role of genetic factors can be assumed [4]. However, there
are no consequently replicable findings about common
polymorphisms associated with antidepressant response [5].* Correspondence: thadeous.smith@gmail.com
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unless otherwise stated.One possible explanation is that antidepressant response
is a multifactorial and polygenic phenotype determined by
several common variants, and each individual SNP is only
responsible for a small fraction of heritability which makes
them invisible in statistical analyses with a reliable confi-
dence rate. Nonetheless, rare genetic variants generally
have a larger impact; so, this might give us hope to iden-
tify genetic variants with more impressing effects, al-
though the current sample sizes of most studies are too
small to detect them [6]. Furthermore, environmental
factors such as childhood maltreatment and stressful life
events in several studies showed independent effects on
selective serotonin reuptake inhibitor (SSRI) response,
and in some cases, also in significant interaction with
genetic polymorphisms [7,8]. Although there are several
genes showing consistent interaction with certain envir-
onmental factors in the development of depression, only
a fraction of these interactions was tested in the case ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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view, we aimed to summarize our current knowledge
about the possible genetic pathways and variants associ-
ated with antidepressant response, and potentially inter-
acting with environmental predictors, focusing on the
widely used SSRIs and their investigation in large-scale
GWA-studies including STAR*D, GENDEP, and MARS.
Methods
We searched PubMed using search terms ‘antidepressant
treatment response’ or ‘SSRI treatment response’ AND
‘gene x environment’ or ‘genetic’ or ‘GWAS’. We included
papers on human subjects published in English language
before 2014 February. Next, the retrieved abstracts were
investigated for quality of evidence. We also included pa-
pers from the reference lists of included studies. The main
focus of the present review was large-scale GWA-studies
including STAR*D, GENDEP, and MARS. Regarding can-
didate gene studies, detailed reviews are available [9,14];
therefore, we only discussed genes that are likely to show
gene-by-environment interactions (G × E). Namely, the
serotonin transporter gene (SLC6A4), as the gene encod-
ing the main target of SSRIs, and the most investigated
genes involved in neuroplasticity/neurodevelopment and
inflammation that also have major roles in antidepressant
response based on animal studies [15]. Thus, the present




Lesch et al. in 1996described a SLC6A4 gene-linked
polymorphic region (5-HTTLPR) upstream of the 5-HTT
coding sequence (SLC6A4), having a short and long vari-
ant which robustly influences transcriptional activity. In
this study, carriers of two long alleles synthesized 1.4 toTable 1 Positive results for gene-environment interactions be
Gene variant Interacting factor Outcome
5-HTTLPR Stressful life events Escitalopram respo







5-HTR1B with negative life events,
TPH2 with childhood trauma
Antidepressant
treatment respons1.7 times more mRNA compared to those who carried the
short variant at least in one copy [16]. Lesch et al. have
found an association between 5-HTTLPR and the neuroti-
cism personality trait as measured by NEO-PI-R, which
has been identified as a risk factor in the development of
MDD. Subsequently, several studies attempted to clarify
the link between MDD and 5-HTTLPR, with contradict-
ory results. One of the most recent meta-analyses con-
cluded that it has a small but significant effect; however,
the authors warn about publication bias that might inter-
fere with these findings [17].
The main site of action of SSRIs is the 5-HTT protein,
so extensive research started in order to find the link be-
tween 5-HTTLPR and SSRI response. Studies in mixed-
race samples yielded contradictory findings, however, in
Caucasian patient samples there is suggestive evidence
pointing to better SSRI response associated with presence
of the long allele [18].
Besides the independent effects of 5-HTTLPR, its inter-
actions with environmental factors (G × E interactions)
were also reported. Short allele carriers who also experi-
enced childhood maltreatment and recent life events
showed increased vulnerability to stress, increased severity
of depression, and reported persistent MDD rather than
single, time-limited episodes [7,8,19]. Depression severity
is a well-known risk factor of unfavorable treatment re-
sponse [6], and childhood maltreatment is one of the main
environmental predictors of severe depression [20]. Thus,
it can be assumed that childhood maltreatment in inter-
action with the 5-HTTLPR can influence SSRI efficacy, al-
though it has not been tested as yet. However, 5-HTTLPR
significantly interacted with recent stressful life events on
escitalopram efficacy [10]. This interaction suggests that
genetic polymorphisms alone have rather poor predicting
capabilities but with their specific environmental interac-




nse 674 [10] Montgomery-Asberg Depression Rating
Scale (MADRS),
List of Threatening Experiences
questionnaire(LTE-Q)
nse 159 [11] Hamilton Rating Scale for Depression (HAMD)
Life Events and Difficulty Schedule(LEDS)
e
308 [12] Hamilton Depression Rating Scale (HDRS-17)
Childhood Trauma Questionnaire(28 item
Short Form, CTQ-SF)
e
308 [13] Hamilton Depression Rating Scale (HDRS-17)
Childhood Trauma Questionnaire(28-item
Short Form, CTQ-SF)
Life Events Scale (LES)
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the SLC6A4 gene were identified and in some cases,
found to be associated with SSRI response. For example,
in a large-scale study, Stin4 showed similar interaction
with stressful life events and modified SSRI response in-
dependent of 5-HTTLPR [10]. Furthermore, an SNP has
been identified within the long allele of 5-HTTLPR
which could abolish the greater expression rate of the
long variant, making it functionally equal to the short vari-
ant [21]. Therefore, we can conclude that 5-HTTLPR has
important interactions with other genetic variants within
the serotonin transporter gene (SLC6A4) and possibly with
other genes and environmental stressors, so examining its
effect independently from all other factors seems to be an
ineffective approach. Rather, focusing on the interactions
of 5-HTTLPR already produced valuable information con-
cerning SSRI response, and could possibly aid biomarker
research for personalized treatment in the future.Neuroplasticity: BDNF
Brain-derived neurotrophic factor (BDNF) is the most
common neurotrophin in the human brain. It has a con-
firmed role in brain development and synaptic plasticity,
and via these biological processes, it modulates personal-
ity development and cognitive functions [22]. According
to early animal studies, BDNF showed promising features
to be a probable biomarker for depression. BDNF infusion
to the midbrain reduced pain sensitivity and learned help-
lessness in rat models of depression [23], while other reports
found elevated BDNF levels in SSRI-treated animals [24].
Indeed, physiological relationships have been identified
between 5-HT and BDNF in neurogenesis and neuro-
plasticity. They activate intracellular cascades leading to
the activation of the same set of transcriptional factors,
(e.g. cAMP response element-binding protein(CREB),
CREB-binding protein (CBP), forkhead box protein O
(FOXO), nerve growth factor-inducible factor A (NGFI-
A)) which can prevent cell death or induce neuronal
growth [25]. Experimental evidence is available about
the facilitating effect of SSRIs on cognitive functions,
spatial memory, hippocampal neurogenesis, and brain
recovery after injury possibly through increased BDNF
production [25].
A common SNP (rs6265) in the coding exon of the
BDNF gene leading to a valin (Val) to methionin (Met)
change has been identified, and examined comprehensively
with the minor, Met coding variant showing reduced activ-
ity and contributing to the development of MDD, especially
in elderly patients; while the higher activity Val allele was
associated with bipolar depression, and substance abuse
according to a recent meta-analysis [22]. The Val66Met
polymorphism alters the regulated release of BDNF, while
the constitutive release remains intact. In addition, Met66carriers often exhibit poorer episodic memory, and abnor-
mal hippocampal activity [26].
Many studies investigating the efficacy of SSRIs yielded
inconsistent results about the Val66Met polymorphism,
and the hypothesis of Val66 variant facilitating better re-
sponse is not confirmed [14,27]. Some reports even
found the Met66 allele associated with better response
to SSRIs [28]. However, it is important to note that in
animal models, overexpression of BDNF in the hippo-
campus causes antidepressant-like effect while in the
ventral tegmental area or nucleus accumbens, it is associ-
ated with depression-like behavior [29,30]. These results
suggest that proper BDNF function which is a crucial me-
diator of activity-dependent neuronal plasticity is import-
ant for a favorable SSRI response. In addition, other
factors should be taken into consideration in the case of
BDNF’s effect on SSRI efficacy.
A recent meta-analysis found a significant interaction
between stressful life events and BDNF Val66Met poly-
morphism. Met66 carriers showed a higher probability
to develop depression if stressful life events were present
[31]. Another study reported a more complex inter-
action, where the Met66 variant with other SNPs in the
BDNF-TRkB-CREB1 pathway showed interaction with
childhood adversity and increased the risk for depres-
sion, while the Val66 variant among other SNPs was as-
sociated with a maladaptive cognitive response style for
life stress, called rumination, which is also a risk factor
for depression [32]. It seems likely that both alleles of
the Val66Met polymorphism of BDNF have their own
spectrum of vulnerability by modulating consequences
of specific environmental factors, and therefore, they
cannot be generalized as either favorable or unfavorable
alleles. Moreover, it is important to note that introdu-
cing intermediate phenotypes, like rumination, hippo-
campal volume or stress hormone response, can uncover
novel mechanisms that are responsible for contradictory
findings in gene-main effect studies. Intermediate phe-
notypes are genetically determined traits that in neuro-
psychiatry represent neurobiological processes with a
causal role in the disease pathway [33,34]. Considering
these, a comprehensive analysis of BDNF G × E inter-
action effects on SSRI response and using intermediate
phenotypes of antidepressant response could explain
more variability than previous studies focusing on the
independent effects of the SNPs and only one outcome
measure. Unfortunately, there is no such study available
yet, partially due to the difficulty of reliably measuring
complex environmental factors.
Another important confounding factor is the depend-
ence of BDNF gene expression on an enormous number
of other genes, and their polymorphisms in the neuro-
plasticity pathway. For example, in rat models, SSRI
treatment could not increase BDNF levels and exert its
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Nonetheless, a large-scale mRNA expression study which
measured changes in SSRI-treated mice found that the
signaling pathway including BDNF-TrkB-CREB1 showed
the best association with SSRI treatment [35]. Thus, search-
ing for SNPs associated with the BDNF pathway in inter-
action with environmental factors seems now a fruitful
approach for candidate gene studies to produce useable
results.
Inflammation
Despite the fact that the monoaminergic theory is the
currently accepted hypothesis of MDD, there is undeni-
able evidence about the existence of several other factors
playing the role in the background of depression including
inflammation-associated processes. In the wide comorbid-
ity spectrum of MDD, there are many disorders associated
with strong underlying inflammatory mechanisms [36].
Moreover, in MDD patients compared to controls a sig-
nificantly higher concentration of proinflammatory cyto-
kines, such as TNF-α, IL-1β, and IL-6 can be measured
[37]. In addition, administration of TNF-α antagonist eta-
nercept to patients with psoriasis was reported to reduce
MDD symptoms. In contrast, IFN-α and IL-2 treatment
induces depressive symptoms as a common side effect
[38]. Based on these observations, we can conclude that
the inflammation pathway has a significant effect in de-
pression. However, antidepressant treatment also has an
effect on inflammatory processes, namely they lowered
the levels of IL-1β, and specifically SSRI treatment re-
duced the IL-6 levels in MDD patients in a recent meta-
analysis [39].
Another recently proposed possible biochemical link
between 5-HT and inflammation may also explain the
relationship between depression and inflammation. 5-HT
synthesis from tryptophan can be altered by proinflam-
matory cytokines, through the increased activation of
indolamine-2,3-dioxygenase (IDO). IDO activation pro-
motes the production of kynurenine from tryptophan
instead of 5-HT, and kynurenine has two NMDA agon-
ist metabolites with neurotoxic properties [40]. There is
experimental evidence that polymorphisms in the IDO1
and IDO2 genes significantly modulated citalopram re-
sponse possibly by decreasing the availability of neuro-
toxic kynurenine pathway products [41,42].
There are several possible mechanisms proposed besides
the effect on tryptophan bioavailability and neurotoxic
kynurenine metabolites which can cause inflammation-
associated MDD. Adaptive immune functions are impaired
in MDD according to several reports, so the balance be-
tween proinflammatory and anti-inflammatory cytokines
is disturbed. The prolonged pro-inflammatory effects
cause increased glucocorticoid production and increased
hypothalamic-pituitary-adrenal (HPA) axis activity. Theseconsequently damage hippocampal neurons, and contribute
to the development of MDD. Pro-inflammatory cytokines
also disturb neurogenesis and synaptic plasticity through
microglial activation, which negatively influence the sur-
vival rate of new hippocampal neurons [43].
Considering G × E interactions, a polymorphism
(rs1360780) in the FKBP5 gene which codes a protein
with a major role in HPA axis regulation interacts with
childhood maltreatment on depression severity and de-
velopment [44]. Although this gene influenced anti-
depressant response in the STAR*D study, there is no
data published whether it is modulated by life stresses
[45]. Glucocorticoid receptor gene (NR3C1) polymor-
phisms were also found to be predictors of response to
both tricyclic and SSRI antidepressants on a large sam-
ple of MDD patients [27]. These findings suggest that
preventing production of proinflammatory cytokines
can possibly increase efficacy of antidepressants. For
example, celecoxib combined with SSRIs showed sig-
nificantly better efficacy than placebo plus SSRI [43],
although some contradictory findings were also pub-
lished [46,47].
In summary, SSRIs down-regulate proinflammatory
processes while anti-inflammatory treatment may enhance
SSRI efficacy. Nevertheless, the role of inflammation
on the outcome of antidepressant treatment is usually
neglected, despite the fact that several well-established
lines of evidence suggest its importance. Taking biomarkers
of inflammation into account in genetic association studies
on antidepressant treatment, similarly to other environ-
mental effects such as childhood maltreatment or stressful
life events, may reveal several new aspects of SSRI efficacy.
However, there is no such study published as yet to the
best of our knowledge. A possible difficulty of these stud-
ies is that ‘classic’ environmental factors such as stressful
life events already include conditions which have a unique
and well-described relationship with inflammation, like
different medical illnesses. Therefore, a more precise
measurement of environmental effects is required to
improve the future G × E interaction studies consider-
ing inflammation-associated gene regions.
Other potential mechanisms
There are many candidate gene studies which provided
promising results about genes and polymorphisms related
to antidepressant response, for example in cannabinoid,
glutamate, dopamine, or norepinephrine pathways [48,49].
Comprehensive discussion of these pathways is beyond
the scope of the present paper which focuses on G × E
interactions. Furthermore, we only aimed to represent
findings of antidepressant treatment response, not de-
pression as a disorder, on which a thorough discussion
can be found in other recent papers, e.g., by Mandelli
and Serretti [9].
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Genome-wide association studies (GWAS) use entirely dif-
ferent methods than previously presented candidate gene
studies. GWAS do not rely on a set of genes expected to
predict the outcome. The inclusion criterion is merely the
minor allele frequency (MAF), which describes the occur-
rence rate of the polymorphism. Therefore, GWAS scan
hundred thousands of SNPs in an appropriately large sam-
ple of patients. The high volume of genotyped samples give
immense statistical power to GWAS studies, however, way
more rigorous significance levels (p ≤ 5 × 10−8) have to be
employed in order to avoid false-positive results. In the
following three sections, we would like to review the three
biggest GWAS studies on antidepressant efficacy.
GENDEP
The Genome-based Therapeutic Drugs for Depression
(GENDEP) study examined 706 MDD patients treated
with nortriptyline or escitalopram for 12 weeks. On a
genome-wide significance level, the gene coding uronyl-
2-sulphotransferase (UST) was associated with nortripty-
line response. On a suggestive level, IL-11 expression was
associated with escitalopram response, and two intergenic
regions on chromosome 1 and 10 were found to be linked
with response to both medications. On a lower level of
significance, IL-6 appeared as a noticeable modulator,
which further supports the significance of the role of the
proinflammatory pathway in SSRI efficacy and the inflam-
mation theory of depression. The other identified pre-
dictor regions were pretty unexpected. UST is an enzyme
necessary to produce oversulfated proteoglycans, influen-
cing neurogenesis, and neuronal migration. The intergenic
polymorphism found on chromosome 1 is close to the cod-
ing sequence expressing zinc finger protein 326 (ZNF326).
On chromosome 10, the closest gene is the plexin domain
containing 2 (PLXDC2). They are both involved in the
structural changes of chromatin, but the exact mechanism
on SSRI effect is unknown. However, these findings sug-
gest that polymorphisms in non-coding areas which pos-
sibly influence the transcription rate of other gene-coding
regions have the same or even more power to modulate
SSRI efficacy [50].
Besides genetic factors, age, depression severity, and
stressful life events showed significant association with
SSRI response. Younger patients with the lowest baseline
depression severity showed better response to escitalo-
pram. Interestingly, subjects with one or more stressful
life events also responded better to escitalopram, sug-
gesting the role of the serotonergic system in the devel-
opment of life stress-induced depression [10].
STAR*D
In the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) study, all 1,493 patients were treatedinitially with citalopram in a naturalistic design, with no
placebo control or serum level assessments to filter out no
real medication effect and non-compliance [51]. There
was no genome-wide significant association found among
the 430,198 SNPs tested. The top two associated polymor-
phisms were in non-coding areas, one is between the ubi-
quitin protein ligase E3C gene (UBE3C) and motor neuron
and pancreas homebox 1 (MNX1 or HLXB9), and the
other is near the bone morphogenic protein 7 (BMP7)
gene. UBE3C signals proteins for degradation, and MNX1
has a role in embryonic brain development. Just like in
GENDEP, the top findings are in non-coding regions,
close to non-expected genes [52]. Comparing the genetic
properties of sustained responder groups to those of non-
sustained responders, the top 25 SNPs were again intronic
or intergenic. Although there is a lower chance of placebo
effect or non-compliance in sustained responder than in
non-sustained responders, the STAR*D top findings were
non-replicable in the GENDEP sample [53].
Apart from genetic features, minority status, socioeco-
nomic disadvantage, comorbid conditions, lower function-
ing and quality of life, and anxious or melancholic features
were found to be unfavorable on the outcome [54]. Among
the sociodemographic predictors, simultaneous presence
of higher education, higher income, not living alone,
and good employment status were highly correlated
with remission [55].
MARS
The Munich Antidepressant Response Signature (MARS)
included 339 patients, 88.8% with MDD and 11.2% with
BPD, all of whom were Caucasian, and 85.1% from German
descent [56].The CDH17 gene polymorphism rs6989467
showed the most significant association with treatment
outcome. The genome-wide testing was also accomplished
on an independent German sample (n = 361), and an inter-
genic SNP between AK090788 and PDE10A genes showed
the strongest association. None of these findings could
achieve genome-wide significance, and the authors con-
cluded that these genes have a rather modest effect on
SSRI response. Suspecting multiple genes, pathway ana-
lysis was performed, which identified three gene clusters.
The first cluster is centered on fibronectin 1 (FN1), in-
cluding transcriptional factors and the substrate, and re-
ceptor genes of ephrin-A5, which has a role in late-stage
nervous system development, and is associated with hip-
pocampal neural plasticity. The second cluster has risk
genes for cardiovascular and metabolic disorders, which
show a high comorbidity with depression, and the third is
related to GABA and glutamatergic neurotransmission
[56]. Signaling pathway analysis is a progressive approach
to identify genes with cumulating effects on complex phe-
notypes like depression, and could be a very fruitful way
to search for potential target molecules in the future.
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tested by the combined dexamethasone suppression/
CRH stimulation (DEX-CRH) test. As proposed earlier,
HPA hyperactivity most likely caused by impaired nega-
tive feedback control in MDD patients was associated
with depression severity. After 5 weeks of antidepres-
sant treatment, normalization in HPA hyperactivity was
observed in remitters, but not in non-remitters. A sin-
gle DEX-CRH in males and repeated tests in females
were able to predict antidepressant treatment outcome
[57]. Therefore, testing HPA axis function, as a biomarker
of the body response to environmental stressors, seems to
be an interesting approach to predict SSRI efficacy prior
to treatment.Meta-analysis
The three studies above were summarized by a meta-
analysis, which could not find a genome-wide significant
association in case of any of the 1.2 million analyzed poly-
morphisms [5]. Although the authors concluded that there
are no reliable predictor gene regions or a set of common
SNPs, valuable conclusions could be made about the rele-
vance and capabilities of GWAS studies. Methodological
problems such as definition of responders/non-responders,
or choosing the inclusion criteria, and determining the
study design can cause more interference with the results
if they are expected to meet the GWAS level of signifi-
cance [51]. Individual differences in symptom trajectories
were found to be important predictors of treatment out-
come itself further supporting that MDD is a heteroge-
neous disorder. For example, patients with less activity
and lack of interest showed worse response to antidepres-
sant treatment [58]. In contrast, cognitive symptoms were
found to be more responsive to SSRI treatment [59].
Based on this experience, the more accurate declaration of
our expectations on SSRI response should help find more
significant associations. Moreover, integrating measures of
non-subjective intermediate phenotypes in the symptom
trajectory seems to be a promising approach. For example,
neuroimaging-based intermediate phenotypes can help us
better understand the brain processes behind symptom
trajectories [60]. Although it is not possible to scan enough
patients with neuroimaging techniques for a GWA study,
these results can help us refine our phenotype-measuring
system and develop more biology-related categories to
work with.
Another crippling deficiency of the GWAS approach is
ignoring environmental factors, while in many cases, they
show better association with the response than genetic
polymorphisms [55]. In the future, new more powerful
statistical methods, like the Bayesian network analysis,
must be developed in order to take environmental fac-
tors into consideration [61,62].Limitations of genetic studies on antidepressant
response
The limitation of G × E interaction studies in psychiatric
disorders was discussed comprehensively in a recent re-
view by Uher [7]. Therefore, here we only highlight
some major points. One important problem is the het-
erogeneity of the measured phenotypes. We mentioned
above that the inconsistent definition of responders or
non-responders, the lack of detailed investigation of
symptom trajectories (e.g.: anhedonia versus cognitive
symptoms) and antidepressant response-related inter-
mediate phenotypes all hinder the identification of gen-
etic risk factors. In addition, recall bias and the use of
different life stressor measures confounds present find-
ings related to environmental factors. A more detailed
and precise measure of life stresses is required because
certain genes only shape the vulnerability profile toward
specific life events, e.g., early versus late life events seem
to have different interaction patterns with certain genes
and polymorphisms. However, they could be equally im-
portant. Early life stressors exert their effects on a devel-
oping brain that facilitates more intense changes in
neural circuits which can exert long-standing negative
effects. However, recent negative life events frequently
trigger a cascade that eventually leads to negative neuro-
plastic changes. Another major problem is that present
statistical methods are not powerful enough to detect
G × E interactions with biological consequences and can-
not handle such big datasets as would be required for
genome-wide G × E (GEWI) studies. Therefore the de-
velopment of new statistical methods is essential for fur-
ther results. An additional problem in these studies is
that hidden relatedness within the population or differ-
ent ethnicity may cause stratification bias. For example,
there are several differences between Caucasian and
Asian patients considering the genetic background of
antidepressant response. Although GWAS studies con-
trol their calculations for possible stratification biases by
using specific ancestry markers, these are usually not
available for candidate gene studies.
Discussion
Investigation of common polymorphisms associated with
antidepressant response showed contradictory results,
even in case of logical target genes like SLC6A4. Recent
meta-analyses only found a very small effect in the case
of these polymorphisms [17], and many times, other
SNPs were found to change the effect of the initial SNP
[21,63,64], suggesting a more complex interaction than a
one-SNP-one-phenotype relationship.
While candidate gene studies could not produce rep-
licable results, GWAS found a multitude of genes and
pathways related to antidepressant response, but the ma-
jority could not meet the strict statistical significance
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multiple testing were not replicable by other GWAS.
The heterogeneity of GWAS results suggests that mul-
tiple common variants are involved in the response with
a cumulative effect [5]. GWAS also highlighted the im-
portance of genes involved in brain development and
hippocampal neural plasticity besides the monoaminer-
gic pathways.
Epigenetic factors were also identified. These changes
such as methylation, or acetylation are tissue-specific,
and caused by the combined effect of the DNA and en-
vironmental factors. Unfortunately the tissue-specific
localization makes them only examinable in post-
mortem studies with a smaller sample size, but these
studies reported much larger changes in the brain than
polymorphisms could ever cause [65]. Despite the accu-
mulating evidence that G × E is a major factor in anti-
depressant response only a handful studies are available
so far (Table 1).
As we can see the multiple steps between the exam-
ined SNPs and the outcome (which is often declared
subjectively), it is reasonable why there were no replicable
findings about the effect of common SNPs on antidepres-
sant response. The magnitude of epigenetic effects com-
bined with the multiple findings about environmental
interactions must change our expectations about genetic
studies [66,67]. A new model of depression proposes that
each person has an individual vulnerability profile towards
MDD, and MDD develops through personal maladaptive
processes to cope with environmental effects. According
to our current understanding, there is no common poly-
morphism with absolute effect on MDD, they just shape
the vulnerability profile with distinct effects [68,69]. For
example, the 5-HTTLPR's short variant induces vulner-
ability to stressful life events, but short-short carrier
children seem to be more responsive to cognitive behav-
ior therapy [70].
Therefore, the next step should be to better identify
outcome variables, if we want to find significant, replic-
able, and useful predictors to antidepressant response.
Remission and even depression should be described
from a biological approach. For example, intermediate
phenotypes such as HPA axis hyperactivity, pro-
inflammatory cytokine concentrations or hippocampal
volume, are more manageable variants for a genetic re-
search than medical symptomatology [71]. We also have
to move forward in the genetic approach of this ques-
tion. A multitude of studies showed that even without
the effect of the environmental factors, countless inter-
actions are present among genetic variants, and they
often entirely change the effect of an individual poly-
morphism. Besides that, environmental effects cannot
be neglected anymore. Epigenetic studies showed us the
power of combining the effect of environmental factorsand genetic properties, and in the future, we shall find a
way to utilize it.
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